Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OGN – Organon & Co.

Organon & Co.
OGN
$13.05
Name : Organon & Co.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $3,366,247,424.00
EPSttm : 3.33
finviz dynamic chart for OGN
Organon & Co.
$13.05
9.69%
$1.40

Float Short %

7.14

Margin Of Safety %

52

Put/Call OI Ratio

0.69

EPS Next Q Diff

0.01

EPS Last/This Y

0.49

EPS This/Next Y

0.18

Price

13.03

Target Price

20

Analyst Recom

2.67

Performance Q

-12.77

Relative Volume

1.5

Beta

0.68

Ticker: OGN




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-10OGN15.750.450.1154687
2025-03-11OGN15.610.450.3554984
2025-03-12OGN15.010.450.2955087
2025-03-13OGN14.960.450.9355381
2025-03-14OGN15.310.450.4755793
2025-03-17OGN15.620.450.4355835
2025-03-18OGN15.70.450.8656007
2025-03-19OGN15.80.450.3156172
2025-03-20OGN15.60.451.3656386
2025-03-21OGN15.380.460.6656806
2025-03-24OGN15.340.640.4041909
2025-03-25OGN14.720.650.7443012
2025-03-26OGN14.720.640.6144132
2025-03-27OGN14.560.631.0045175
2025-03-28OGN14.520.642.3845763
2025-03-31OGN14.880.640.9945928
2025-04-01OGN14.120.641.8546464
2025-04-02OGN14.720.653.4146758
2025-04-03OGN14.450.690.4548647
2025-04-04OGN13.030.690.9048696
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-10OGN15.74-25.6- 3.85
2025-03-11OGN15.62-25.6- 3.84
2025-03-12OGN15.00-25.6- 3.84
2025-03-13OGN14.96-25.6- 3.84
2025-03-14OGN15.31-25.6- 3.84
2025-03-17OGN15.62-25.6- 3.84
2025-03-18OGN15.70-25.6- 3.84
2025-03-19OGN15.79-25.6- 3.84
2025-03-20OGN15.60-25.6- 3.84
2025-03-21OGN15.38-25.6- 3.84
2025-03-24OGN15.33-25.6- 3.84
2025-03-25OGN14.72-25.6- 3.84
2025-03-26OGN14.71-25.6- 3.84
2025-03-27OGN14.56-25.6- 3.84
2025-03-28OGN14.51-25.1- 3.85
2025-03-31OGN14.89-25.1- 3.85
2025-04-01OGN14.13-25.1- 3.85
2025-04-02OGN14.72-25.1- 3.85
2025-04-03OGN14.45-25.1- 3.85
2025-04-04OGN13.03-25.1- 3.85
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-10OGN0.003.137.17
2025-03-11OGN0.003.137.17
2025-03-12OGN0.003.136.93
2025-03-13OGN0.003.136.93
2025-03-14OGN0.003.136.93
2025-03-17OGN0.002.926.93
2025-03-18OGN0.002.926.93
2025-03-19OGN0.002.926.93
2025-03-20OGN0.002.926.93
2025-03-21OGN0.002.926.93
2025-03-24OGN0.002.906.93
2025-03-25OGN0.002.906.93
2025-03-26OGN0.002.907.14
2025-03-27OGN0.002.907.14
2025-03-28OGN0.002.907.14
2025-03-31OGN0.002.907.14
2025-04-01OGN0.002.907.14
2025-04-02OGN0.002.907.14
2025-04-03OGN0.002.907.14
2025-04-04OGN0.002.907.14
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

0.9

Avg. EPS Est. Current Quarter

0.91

Avg. EPS Est. Next Quarter

0.91

Insider Transactions

Institutional Transactions

2.9

Beta

0.68

Average Sales Estimate Current Quarter

1533

Average Sales Estimate Next Quarter

1555

Fair Value

19.86

Quality Score

82

Growth Score

67

Sentiment Score

57

Actual DrawDown %

67

Max Drawdown 5-Year %

Target Price

20

P/E

3.91

Forward P/E

3.24

PEG

13.5

P/S

0.53

P/B

7.13

P/Free Cash Flow

4.41

EPS

3.33

Average EPS Est. Cur. Y​

3.85

EPS Next Y. (Est.)

4.03

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

13.49

Relative Volume

1.5

Return on Equity vs Sector %

163.2

Return on Equity vs Industry %

156.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.04

EBIT Estimation

Organon & Co.
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 10000
Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
stock quote shares OGN – Organon & Co. Stock Price stock today
news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025
marketwatch OGN – Organon & Co. yahoo finance google finance
stock history OGN – Organon & Co. invest stock market
stock prices OGN premarket after hours
ticker OGN fair value insiders trading